These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33586037)

  • 1. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
    Abdulfatah E; Reichert ZR; Davenport MS; Chinnaiyan AM; Dadhania V; Wang X; Mannan R; Kunju LP; Hollenbeck BK; Montgomery JS; Kaffenberger SD; Morgan TM; Alva AS; Palapattu GS; Vaishampayan UN; Alumkal JJ; Spratt DE; Udager AM; Mehra R
    Med Oncol; 2021 Feb; 38(3):26. PubMed ID: 33586037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
    Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
    Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.
    Gunia S; Albrecht K; Koch S; Herrmann T; Ecke T; Loy V; Linke J; Siegsmund M; May M
    World J Urol; 2008 Jun; 26(3):243-50. PubMed ID: 18392627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
    Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.
    Dankert JT; Wiesehöfer M; Czyrnik ED; Singer BB; von Ostau N; Wennemuth G
    PLoS One; 2018; 13(7):e0200472. PubMed ID: 30001402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
    Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
    Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review.
    Acosta-Gonzalez G; Qin J; Wieczorek R; Melamed J; Deng FM; Zhou M; Makarov D; Ye F; Pei Z; Pincus MR; Lee P
    Am J Clin Exp Urol; 2014; 2(4):337-42. PubMed ID: 25606580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
    Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
    Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer.
    Kryvenko ON; Williamson SR; Trpkov K; Gupta NS; Athanazio D; Selig MK; Smith PT; Magi-Galluzzi C; Jorda M
    Virchows Arch; 2017 Jan; 470(1):47-54. PubMed ID: 27743032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificities of small cell neuroendocrine prostate cancer: Adverse prognostic value of TTF1 expression.
    Cancel M; Castellier C; Debiais-Delpech C; Charles T; Rozet F; Rioux-Leclercq N; Mathieu R; Beltjens F; Cormier L; Bruyère F; Fromont G
    Urol Oncol; 2021 Jan; 39(1):74.e17-74.e23. PubMed ID: 32739231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
    Gordetsky J; Epstein JI
    Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
    Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
    Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
    Mohanty SK; Lobo A; Williamson SR; Shah RB; Trpkov K; Varma M; Sirohi D; Aron M; Kandukari SR; Balzer BL; Luthringer DL; Ro J; Osunkoya AO; Desai S; Menon S; Nigam LK; Sardana R; Roy P; Kaushal S; Midha D; Swain M; Ambekar A; Mitra S; Rao V; Soni S; Jain K; Diwaker P; Pattnaik N; Sharma S; Chakrabarti I; Sable M; Jain E; Jain D; Samra S; Vankalakunti M; Mohanty S; Parwani AV; Sancheti S; Kumari N; Jha S; Dixit M; Malik V; Arora S; Munjal G; Gopalan A; Magi-Galluzzi C; Dhillon J
    Int J Surg Pathol; 2023 Sep; 31(6):993-1005. PubMed ID: 35946087
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical, pathologic, and molecular features of amphicrine prostate cancer.
    Graham LS; Haffner MC; Sayar E; Gawne A; Schweizer MT; Pritchard CC; Coleman I; Nelson PS; Yu EY
    Prostate; 2023 May; 83(7):641-648. PubMed ID: 36779357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells.
    Quirós I; Sáinz RM; Hevia D; García-Suárez O; Astudillo A; Rivas M; Mayo JC
    Int J Cancer; 2009 Oct; 125(7):1497-504. PubMed ID: 19507253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series.
    Gopalan A; Al-Ahmadie H; Chen YB; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Fine SW
    Histopathology; 2022 Aug; 81(2):246-254. PubMed ID: 35758203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.
    Sotomayor P; Godoy A; Smith GJ; Huss WJ
    Prostate; 2009 Mar; 69(4):401-10. PubMed ID: 19058139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.